Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
04 09 2021
Historique:
received: 18 12 2020
revised: 20 03 2021
accepted: 01 04 2021
pubmed: 6 5 2021
medline: 15 12 2021
entrez: 5 5 2021
Statut: ppublish

Résumé

Cerebellar ataxias represent a heterogeneous group of disabling disorders characterized by motor and cognitive disturbances, for which no effective treatment is currently available. In this randomized, double-blind, sham-controlled trial, followed by an open-label phase, we investigated whether treatment with cerebello-spinal transcranial direct current stimulation (tDCS) could improve both motor and cognitive symptoms in patients with neurodegenerative ataxia at short and long-term. Sixty-one patients were randomized in two groups for the first controlled phase. At baseline (T0), Group 1 received placebo stimulation (sham tDCS) while Group 2 received anodal cerebellar tDCS and cathodal spinal tDCS (real tDCS) for 5 days/week for 2 weeks (T1), with a 12-week (T2) follow-up (randomized, double-blind, sham controlled phase). At the 12-week follow-up (T2), all patients (Group 1 and Group 2) received a second treatment of anodal cerebellar tDCS and cathodal spinal tDCS (real tDCS) for 5 days/week for 2 weeks, with a 14-week (T3), 24-week (T4), 36-week (T5) and 52-week follow-up (T6) (open-label phase). At each time point, a clinical, neuropsychological and neurophysiological evaluation was performed. Cerebellar-motor cortex connectivity was evaluated using transcranial magnetic stimulation. We observed a significant improvement in all motor scores (scale for the assessment and rating of ataxia, international cooperative ataxia rating scale), in cognition (evaluated with the cerebellar cognitive affective syndrome scale), in quality-of-life scores, in motor cortex excitability and in cerebellar inhibition after real tDCS compared to sham stimulation and compared to baseline (T0), both at short and long-term. We observed an addon-effect after two repeated treatments with real tDCS compared to a single treatment with real tDCS. The improvement at motor and cognitive scores correlated with the restoration of cerebellar inhibition evaluated with transcranial magnetic stimulation. Cerebello-spinal tDCS represents a promising therapeutic approach for both motor and cognitive symptoms in patients with neurodegenerative ataxia, a still orphan disorder of any pharmacological intervention.

Identifiants

pubmed: 33950222
pii: 6265462
doi: 10.1093/brain/awab157
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2310-2321

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Alberto Benussi (A)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25128 Brescia, Italy.
Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, 25128 Brescia, Italy.

Valentina Cantoni (V)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25128 Brescia, Italy.

Marta Manes (M)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25128 Brescia, Italy.
Neurology Unit, Aulss2 Marca Trevigiana, 31100 Treviso, Italy.

Ilenia Libri (I)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25128 Brescia, Italy.

Valentina Dell'Era (V)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25128 Brescia, Italy.
Department of Neurology, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy.

Abhishek Datta (A)

Research and Development, Soterix Medical, Inc., New York, NY 10001, USA.

Chris Thomas (C)

Research and Development, Soterix Medical, Inc., New York, NY 10001, USA.

Camilla Ferrari (C)

Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, 50130 Florence, Italy.

Alessio Di Fonzo (A)

Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, 20122 Milan, Italy.

Roberto Fancellu (R)

UO Neurologia, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

Mario Grassi (M)

Department of Brain and Behavioural Sciences, Medical and Genomic Statistics Unit, University of Pavia, 27100 Pavia, Italy.

Alfredo Brusco (A)

Department of Medical Sciences, University of Torino, 10124 Torino, Italy.
Medical Genetics Unit, Città della Salute e della Scienza di Torino, 10126 Torino, Italy.

Antonella Alberici (A)

Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, 25128 Brescia, Italy.

Barbara Borroni (B)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, 25128 Brescia, Italy.
Neurology Unit, Department of Neurological and Vision Sciences, ASST Spedali Civili, 25128 Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH